Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas.

The immune system is comprised of two separate active arms of immunity to provide robust protection against disease. The two separate systems of immunity i | Immunology ...

Mammary gland fibroblasts are highly plastic and transition through distinct states during development and disease. A new ...

Scientists at Institut Pasteur have gained new insights into how some people control HIV-1 replication after interruption of antiretroviral treatment (ART). The investigators found a fingerprint ...

Natural killer cells aren't just mindless defenders — a special type, adaptive NK cells, remember their enemies and come back ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced the presentation of new preclinical data ...

Pilatus Biosciences, a biotechnology company developing immunometabolic therapies for cancer, today announced a preclinical publication in Cancer Discovery detailing the mechanism and therapeutic ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...